Jaclyn is a health economist and health services researcher with 15 years of experience in public sector and consulting, supporting provincial governments, cancer agencies, health technology assessment committees and pCPA. She led the Pharmacoeconomics Research Unit at Ontario Health – Cancer Care Ontario providing objective advice and evidence to guide public drug program policy and planning. She has advanced technical and strategic expertise in pharmacoeconomics and has led development of more than 20 submissions and de-novo models to provincial and pan-Canadian drug review processes to address unfunded gaps in the system. Jaclyn also worked closely with CDA-AMC (formerly CADTH) to support interpretation and improvements to economic content in the drug review process, and with the pCPA to provide innovative pricing tools based on economic evidence for negotiations.
She also played an active role in exploring and expanding policy and methods for the generation and use of real-world evidence (RWE) in cancer drug funding as a core member of the Canadian Real-World Evidence for value of Cancer Drugs (CanREValue) Collaboration and has developed data-driven insights and RWE using administrative databases from across Canada.Â
As the Director of Pharmacoeconomics and RWE, Jaclyn collaborates with clients to develop and refine reimbursement strategies with a focus on health technology assessment, clinical evidence generation, pharmacoeconomic evidence strategy, negotiation scenario planning tools and analytics to support submissions and innovative pricing negotiations.
Jaclyn can be reached at Jaclyn@MorseConsulting.ca or (416)-994-4257.